Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
64Cu-Labeled M5A Antibody PET Imaging in Locally Advanced Rectal Cancer
NCT05245786Phase 1Active, not recruiting
- Sponsor
- City of Hope
- Start
- Aug 2022
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Copper Cu 64 anti-CEA monoclonal antibody M5A in rectal cancer, sponsored by City of Hope. Primary endpoint: Number of patients with impactful finding using 64Cu-M5A positron emission tomography (PET) imaging at 3 years. Started Aug 2022; status: active, not recruiting.
02
Drugs
Copper Cu 64 anti-CEA monoclonal antibody M5A
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT05245786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05245786.